Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Seripa

Showing results (131-140 of 225) with videos related to

Pageof 23
Sort By:
Disease Markers|October 2, 2018
Testing a Combination of Markers of Systemic Redox Status as a Possible Tool for the Diagnosis of Late Onset Alzheimer's DiseaseGiovanni Zuliani, Angelina Passaro, Cristina Bosi, et al.
Genes, Chromosomes & Cancer|February 16, 2007
A combined analytical approach reveals novel EXT1/2 gene mutations in a large cohort of Italian multiple osteochondromas patientsEmanuela Signori, Emanuela Massi, Maria Giovanna Matera, et al.
Immunotherapy|August 4, 2016
Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapyFrancesco Panza, Vincenzo Solfrizzi, Davide Seripa, et al.
The Journal of Orthopaedic and Sports Physical Therapy|August 2, 2016
Is Extracorporeal Shockwave Therapy Combined With Isokinetic Exercise More Effective Than Extracorporeal Shockwave Therapy Alone for Subacromial Impingement Syndrome? A Randomized Clinical TrialAndrea Santamato, Francesco Panza, Angela Notarnicola, et al.
Journal of Alzheimer'S Disease : JAD|June 5, 2009
Alcohol drinking, cognitive functions in older age, predementia, and dementia syndromesFrancesco Panza, Cristiano Capurso, Alessia D'Introno, et al.
Dementia and Geriatric Cognitive Disorders|February 28, 2008
Association analysis of GRIN2B, encoding N-methyl-D-aspartate receptor 2B subunit, and Alzheimer's diseaseDavide Seripa, Maria Giovanna Matera, Marilisa Franceschi, et al.
Expert Opinion on Emerging Drugs|August 11, 2020
Anti-amyloid-β protein agents for the treatment of Alzheimer's disease: an update on emerging drugsMadia Lozupone, Vincenzo Solfrizzi, Francesca D'Urso, et al.
Journal of the Neurological Sciences|August 15, 2018
Plasma β-amyloid<sub>1-42</sub> reference values in cognitively normal subjectsChiara Zecca, Rosanna Tortelli, Francesco Panza, et al.
Medicine|September 15, 2018
CYP2D6 genotypes in revolving door patients with bipolar disorders: A case seriesDavide Seripa, Madia Lozupone, Giuseppe Miscio, et al.
Biomed Research International|July 19, 2016
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's DiseaseFrancesco Panza, Vincenzo Solfrizzi, Davide Seripa, et al.
Pageof 23

Showing results (131-140 of 225) with videos related to

Sort By:
Pageof 23
Disease Markers|October 2, 2018
Testing a Combination of Markers of Systemic Redox Status as a Possible Tool for the Diagnosis of Late Onset Alzheimer's DiseaseGiovanni Zuliani, Angelina Passaro, Cristina Bosi, et al.
Genes, Chromosomes & Cancer|February 16, 2007
A combined analytical approach reveals novel EXT1/2 gene mutations in a large cohort of Italian multiple osteochondromas patientsEmanuela Signori, Emanuela Massi, Maria Giovanna Matera, et al.
Immunotherapy|August 4, 2016
Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapyFrancesco Panza, Vincenzo Solfrizzi, Davide Seripa, et al.
The Journal of Orthopaedic and Sports Physical Therapy|August 2, 2016
Is Extracorporeal Shockwave Therapy Combined With Isokinetic Exercise More Effective Than Extracorporeal Shockwave Therapy Alone for Subacromial Impingement Syndrome? A Randomized Clinical TrialAndrea Santamato, Francesco Panza, Angela Notarnicola, et al.
Journal of Alzheimer'S Disease : JAD|June 5, 2009
Alcohol drinking, cognitive functions in older age, predementia, and dementia syndromesFrancesco Panza, Cristiano Capurso, Alessia D'Introno, et al.
Dementia and Geriatric Cognitive Disorders|February 28, 2008
Association analysis of GRIN2B, encoding N-methyl-D-aspartate receptor 2B subunit, and Alzheimer's diseaseDavide Seripa, Maria Giovanna Matera, Marilisa Franceschi, et al.
Expert Opinion on Emerging Drugs|August 11, 2020
Anti-amyloid-β protein agents for the treatment of Alzheimer's disease: an update on emerging drugsMadia Lozupone, Vincenzo Solfrizzi, Francesca D'Urso, et al.
Journal of the Neurological Sciences|August 15, 2018
Plasma β-amyloid<sub>1-42</sub> reference values in cognitively normal subjectsChiara Zecca, Rosanna Tortelli, Francesco Panza, et al.
Medicine|September 15, 2018
CYP2D6 genotypes in revolving door patients with bipolar disorders: A case seriesDavide Seripa, Madia Lozupone, Giuseppe Miscio, et al.
Biomed Research International|July 19, 2016
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's DiseaseFrancesco Panza, Vincenzo Solfrizzi, Davide Seripa, et al.
Pageof 23